Net Present Value Model: Cimzia
Powered by
Unlock hidden opportunities in the NPV industry
Overview
Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis.
Drug Operating Profit Model
Cimzia Drug Details
Certolizumab pegol (Cimzia) is a recombinant Fab antibody fragment, acts as antirheumatic agent. It is formulated as injectable lyophilized powder for solution and pegylated injectable solution for subcutaneous administration. Cimzia in combination with methotrexate (MTX) is indicated for reducing signs and symptoms, inducing major clinical response, and reducing the progression of joint damage as assessed by X-ray, in adult patients with moderately to severely active rheumatoid arthritis (RA), may be used alone for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who do not tolerate MTX, Cimzia alone or in combination with methotrexate (MTX) is indicated for:reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with moderately to severely active psoriatic arthritis (PsA) who have failed one or more disease-modifying anti-rheumatic drugs (DMARDs), reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS) who have had an inadequate response to conventional therapy, for the treatment of adult patients with severe active axial spondyloarthritis, comprising: adults with severe active ankylosing spondylitis who have had an inadequate response, or are intolerant, Non-steroidal anti-inflammatory drugs (NSAIDs), adults with severe active axial spondyloarthritis without radiographic evidence of AS, but with signs Evident inflammation detected by elevated C-reactive protein (CRP) and / or magnetic resonance imaging (MRI), who have had an inadequate response, or are intolerant, to NSAIDs, for reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy, and non-radiographic axial spondyloarthritis (nr-axSpA), and is indicated to treat plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma for which existing treatment methods are not sufficiently effective.Certolizumab pegol (Cimzia) is under development as a combination with MTX for the treatment of rheumatoid arthritis in adult patients with severe active and progressive RA not previously treated with MTX or other DMARDs and interstitial cystitis. It is a new biological entity (NBE). It was also under development for the treatment of Crohn’s disease and polyarticular juvenile idiopathic arthritis. It was also under development for moderate to severe chronic plaque psoriasis and intestitial cystitis.
Report Coverage
GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
Quick View – NPV Data | |||
Drug Name |
|
||
Administration Pathway |
|
||
Therapeutic Areas | |||
Key Manufacturers |
|
||
Drug Development Status |
|
Reasons to Buy
- Better understand the quantitative value of a specific drug
- Create or support internal NPV models to improve accuracy
- Understand the profit a drug is expected to make, taking into account revenue and cost forecasts leveraging public and proprietary data sets.
Frequently asked questions
- All drug sales and forecasts within NPV Model are calculated in our proprietary company based models . In these models, Analyst Consensus forecasts are built by using company-specific broker reports to create the sales forecasts for each Drug and Segment.
- Sales and forecasts are not indication-specific where drugs are approved , or in development, for multiple indications. Please refer to GlobalData’s Disease Analysis reports for indication-specific sales forecasts.
- Risk-adjusted NPVs use GlobalData’s LoA and PTSR for the indication in the highest development stage. Please refer to the Likelihood of Approval methodology for more details on this content.
GlobalData’s NPV Model is a premium model providing a fully-interactive forecasting and valuation tool, driven by Analyst Consensus estimates, enabling users to analyze and customize valuations for pharmaceutical assets including drugs or segments. The tool provides 17-year drug forecasts from companies with sales forecast data in the pharmaceutical industry, including established global firms and emerging biotechs, which allows access to critical information to facilitate strategic decision making around pharmaceutical assets
The NPV Model includes a forecasted Revenue Model, followed by a proprietary Patent Expiry Model, Operating Profit Model, Net Profit (apply Tax rate) and Discounted Cash Flow (apply Discount rates), to derive Net Present Value (NPV) for a chosen pharmaceutical asset
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.